

## United Global Healthcare Fund

大华全球保健基金

Portfolios Factsheet

5 Lipper Leader  
Consistent Return5 Lipper Leader  
Preservation

## Funds Review

## Fund Objective


The investment objective of the Fund is to achieve long term capital growth by investing in securities issued by companies principally involved in the development, production or distribution of products, equipment and/or services related to healthcare, in any part of the world. Such investments would include investing in sub-sectors of the healthcare industry such as medical products, health services, major pharmaceuticals, specialty major pharmaceuticals, and specialty pharmaceuticals.

## Top 10 Holdings (As at 30 Jun 2010)


Shionogi & Company  
Forest Laboratories Inc  
Merck  
Cephalon Inc  
Unitedhealth Grp  
Eli Lilly  
Salix Pharmaceuticals  
Abbott Laboratories  
Mckesson Corp  
Cubist Pharmaceuticals Inc

## Asset Allocation (As at 30 Jun 2010)

## By Country



## By Sector



## Fund Details

## LAUNCH DATE

July 2000

## FUND SIZE

S\$82.97 million

## NAV PRICE

S\$1.564

(as at 30 Jun 10)

## SUBSCRIPTION

Cash &amp; SRS

## INITIAL INVESTMENT

S\$1,000

## SUB INVESTMENT

S\$500

## MANAGEMENT FEE

1.75% p.a.

## SUBSCRIPTION FEE

5% (Cash, SRS)

## MINIMUM RSP

S\$100/month,  
S\$500/quarter

## TRUSTEE

RBC Dexia Trust

## ISIN CODE


SG9999001176

## BLOOMBERG CODE

UNIGHCI SP

## Performance

21st August 00 To 30th June 10, Performance Based in Singapore Dollar, Calculation Index



\*The above chart reflects performance from the first month end of the Fund. ^5% sales charge applied.

Benchmark (BM) : MSCI ACWI Healthcare.

Perf	NAV	NAV^	BM
1 month	-1.64%	-6.55%	0.00%
3 months	-10.01%	-14.51%	-11.08%
6 months	-6.01%	-10.71%	-9.75%
1 year	8.54%	3.11%	5.67%
3 years	-5.80%	-7.39%	-7.87%
5 years	-0.09%	-1.11%	-3.04%
Since Incept	5.18%	4.64%	-1.20%

Source: Lipper, a Thomson Reuters Company • Performance as at 30 Jun 10, SGD basis, with dividends and distributions reinvested, if any.  
• Performance figures for 1 mth till 1 yr show the % change, while those exceeding 1 yr show the average annual compounded return.

## Fund Awards

The Edge-Lipper SG UT Fund Awards 10, 09, 08, 04, 03  
SG S&P Inv. Fund Awards 06, 05, 04, 02  
SG Inv. Fund Awards 01  
S&P Fund Awards Singapore 07

## Contact Details

Hotline (24-hour):

1800 22 22 228

Website: uobam.com.sg

## IMPORTANT NOTICE AND DISCLAIMERS

A prospectus for the fund(s) (the "Fund(s)") may be obtained from the Manager or any of its appointed distributors. Investors should read the prospectus before deciding whether to subscribe for or purchase units in the Fund(s) ("Units"). All applications for Units must be made on application forms accompanying the prospectus or otherwise as described in the prospectus. **Past performance of the Fund(s) or the Manager and any prediction, projection or forecast on the economy or markets are not necessarily indicative of the future or likely performance of the Fund(s) or the Manager.** Any extraordinary performance may be due to exceptional circumstances which may not be sustainable. The value of Units and any income from the Fund(s) may fall as well as rise. The above information is strictly for general information only and must not be construed as an offer or solicitation to deal in Units, nor a recommendation to invest in any company mentioned herein. Investments in unit trusts are not obligations of, deposits in, or guaranteed or insured by UOB, UOBAM, or any affiliates or distributors. An investment in unit trusts is subject to investment risks and foreign exchange risks, including the possible loss of the principal amount invested. Investors may wish to seek advice from a financial adviser before making a commitment to invest in Units. In the event an investor chooses not to seek advice from a financial adviser, the investor should consider carefully whether the Fund(s) is/are suitable for him. UOB Asset Management Ltd Co. Reg. No.: 198600120Z